Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Netai C. Singha,Tara Nekoroski,Chunmei Zhao,Rebecca Symons,Ping Jiang,Gregory I. Frost,Zhongdong Huang,H. Michael Shepard +7 more
TLDR
It is suggested that HAhigh matrix in vivo may form a barrier inhibiting access of both mAb and NK cells, and that PEGPH20 treatment in combination with anticancer mAbs may be an effective adjunctive therapy for HAhigh tumors.Abstract:
Despite tremendous progress in cancer immunotherapy for solid tumors, clinical success of monoclonal antibody (mAb) therapy is often limited by poorly understood mechanisms associated with the tumor microenvironment (TME). Accumulation of hyaluronan (HA), a major component of the TME, occurs in many solid tumor types, and is associated with poor prognosis and treatment resistance in multiple malignancies. In this study, we describe that a physical barrier associated with high levels of HA (HAhigh) in the TME restricts antibody and immune cell access to tumors, suggesting a novel mechanism of in vivo resistance to mAb therapy. We determined that approximately 60% of HER23+ primary breast tumors and approximately 40% of EGFR+ head and neck squamous cell carcinomas are HAhigh, and hypothesized that HAhigh tumors may be refractory to mAb therapy. We found that the pericellular matrix produced by HAhigh tumor cells inhibited both natural killer (NK) immune cell access to tumor cells and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro . Depletion of HA by PEGPH20, a pegylated recombinant human PH20 hyaluronidase, resulted in increased NK cell access to HAhigh tumor cells, and greatly enhanced trastuzumab- or cetuximab-dependent ADCC in vitro . Furthermore, PEGPH20 treatment enhanced trastuzumab and NK cell access to HAhigh tumors, resulting in enhanced trastuzumab- and NK cell–mediated tumor growth inhibition in vivo . These results suggest that HAhigh matrix in vivo may form a barrier inhibiting access of both mAb and NK cells, and that PEGPH20 treatment in combination with anticancer mAbs may be an effective adjunctive therapy for HAhigh tumors. Mol Cancer Ther; 14(2); 523–32. ©2014 AACR .
This article is featured in Highlights of This Issue, [p. 315][1]
[1]: /lookup/volpage/14/315?iss=2read more
Citations
More filters
Journal ArticleDOI
Transport of drugs from blood vessels to tumour tissue.
TL;DR: The aim of this Review is to provide a broad, balanced perspective on the current understanding of drug transport to tumour cells and on the progress in developing methods to enhance drug delivery.
Journal ArticleDOI
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R. Hingorani,Lei Zheng,Andrea J. Bullock,Tara Elisabeth Seery,William P. Harris,Darren Sigal,Fadi Braiteh,Paul S. Ritch,Mark M. Zalupski,Nathan Bahary,Paul E. Oberstein,Andrea Wang-Gillam,W. Wu,Dimitrios Chondros,Ping Jiang,Sihem Khelifa,Jie Pu,Carrie Aldrich,Andrew Eugene Hendifar +18 more
TL;DR: The largest improvement in PFS was observed in patients with HA-high tumors who received PAG, and a similar TE event rate was observed between the treatment groups in stage 2 of the trial.
Journal ArticleDOI
The glycocalyx and its significance in human medicine
John M. Tarbell,Limary M. Cancel +1 more
TL;DR: The overarching conclusions are that (i) the importance of the glycocalyx in human medicine is only beginning to be recognized, and (ii) more detailed studies of glycocalyX involvement in vascular diseases and cancer will lead to novel treatment modalities.
Journal ArticleDOI
Tissue mechanics regulate brain development, homeostasis and disease
TL;DR: The roles of cell and tissue mechanics in brain development, homeostasis and neural degeneration, as well as in brain cancer, are reviewed.
Journal ArticleDOI
Targeting ECM Disrupts Cancer Progression.
TL;DR: The influence of several ECM proteins on these multiple steps of cancer spread is summarized and the promising (pre-)clinical data showing benefits of targeting these ECM macromolecules to prevent cancer progression are highlighted.
References
More filters
Journal ArticleDOI
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
TL;DR: It is demonstrated that Fc-receptor-dependent mechanisms contribute substantially to the action of cytotoxic antibodies against tumors and indicate that an optimal antibody against tumors would bind preferentially to activation Fc receptors and minimally to the inhibitory partner FcγRIIB.
Journal ArticleDOI
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
Guillaume Cartron,Laurent Dacheux,Gilles Salles,Philippe Solal-Celigny,Pierre Bardos,Philippe Colombat,Hervé Watier +6 more
TL;DR: This study showed an association between the FCGR3A genotype and clinical and molecular responses to rituximab, and will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas.
Journal ArticleDOI
EGFR Antagonists in Cancer Treatment
TL;DR: The mechanisms of action of EGFR inhibitors, their anticancer activity, and clinical issues concerning their use in the treatment of patients with cancer are discussed.
Journal ArticleDOI
Hyaluronan: its nature, distribution, functions and turnover
TL;DR: Hyaluronan’s nature, distribution, functions and turnover are studied in detail in a large sample of animals from around the world.
Journal ArticleDOI
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
Paolo P. Provenzano,Carlos Cuevas,Amy Chang,Vikas K. Goel,Daniel D. Von Hoff,Sunil R. Hingorani,Sunil R. Hingorani +6 more
TL;DR: It is shown that systemic administration of an enzymatic agent can ablate stromal HA from autochthonous murine PDA, normalize IFP, and re-expand the microvasculature and in combination with the standard chemotherapeutic, gemcitabine, the treatment permanently remodels the tumor microenvironment and consistently achieves objective tumor responses, resulting in a near doubling of overall survival.
Related Papers (5)
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Michael A. Jacobetz,Derek S. Chan,Albrecht Neesse,Tashinga E. Bapiro,Natalie Cook,Kristopher K. Frese,Christine Feig,Tomoaki Nakagawa,Meredith E. Caldwell,Heather I Zecchini,Martijn P. Lolkema,Ping Jiang,Anne Kultti,Curtis B. Thompson,Daniel C. Maneval,Duncan I. Jodrell,Gregory I. Frost,Harold Michael Shepard,Jeremy N. Skepper,David A. Tuveson +19 more